JP2021508318A5 - - Google Patents

Download PDF

Info

Publication number
JP2021508318A5
JP2021508318A5 JP2020531663A JP2020531663A JP2021508318A5 JP 2021508318 A5 JP2021508318 A5 JP 2021508318A5 JP 2020531663 A JP2020531663 A JP 2020531663A JP 2020531663 A JP2020531663 A JP 2020531663A JP 2021508318 A5 JP2021508318 A5 JP 2021508318A5
Authority
JP
Japan
Prior art keywords
alkyl
halogen
heteroaryl
heterocycloalkyl
heteroalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020531663A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021508318A (ja
JP7319977B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/064114 external-priority patent/WO2019113242A1/en
Publication of JP2021508318A publication Critical patent/JP2021508318A/ja
Publication of JP2021508318A5 publication Critical patent/JP2021508318A5/ja
Application granted granted Critical
Publication of JP7319977B2 publication Critical patent/JP7319977B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020531663A 2017-12-06 2018-12-05 チューブリン阻害剤 Active JP7319977B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762595530P 2017-12-06 2017-12-06
US62/595,530 2017-12-06
PCT/US2018/064114 WO2019113242A1 (en) 2017-12-06 2018-12-05 Tubulin inhibitors

Publications (3)

Publication Number Publication Date
JP2021508318A JP2021508318A (ja) 2021-03-04
JP2021508318A5 true JP2021508318A5 (enExample) 2022-01-11
JP7319977B2 JP7319977B2 (ja) 2023-08-02

Family

ID=66658388

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020531663A Active JP7319977B2 (ja) 2017-12-06 2018-12-05 チューブリン阻害剤

Country Status (8)

Country Link
US (3) US11040945B2 (enExample)
EP (1) EP3720436A4 (enExample)
JP (1) JP7319977B2 (enExample)
KR (1) KR20200104873A (enExample)
CN (1) CN111727042A (enExample)
AU (1) AU2018380132B2 (enExample)
TW (1) TWI828644B (enExample)
WO (1) WO2019113242A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019200683B2 (en) * 2018-02-01 2024-05-30 The University Of Sydney Anti-cancer compounds
AU2019215799B2 (en) * 2018-02-01 2022-04-14 The University Of Sydney Anti-cancer compounds
IL283755B2 (en) 2018-12-07 2026-04-01 Univ Maryland N-(Phenyl-4-methylamino)-5-naphthalene-1-sulfonamide compounds and pharmaceutical preparations containing them
JP2022542434A (ja) * 2019-07-31 2022-10-03 アクラリス セラピューティクス,インコーポレイテッド 重水素化mk2経路阻害剤およびその使用方法
US20210147441A1 (en) * 2019-09-26 2021-05-20 Agency For Science, Technology And Research (A*Star) Therapeutic compounds and methods of use thereof
MX2022007376A (es) 2019-12-20 2022-09-02 Tenaya Therapeutics Inc Fluoroalqull-oxadiazoles y sus usos.
KR20220161396A (ko) 2020-03-27 2022-12-06 어클라리스 쎄라퓨틱스, 인코포레이티드 치환된 피리디논-피리디닐 화합물의 제조, 조성물, 및 결정형
WO2022103149A1 (ko) * 2020-11-10 2022-05-19 주식회사 큐라클 신규한 카바졸 유도체 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
WO2022204046A1 (en) * 2021-03-23 2022-09-29 Gen1E Lifesciences Inc. Substituted naphthyl p38alpha mitogen-activated protein kinase inhibitors
US20240252502A1 (en) 2021-05-04 2024-08-01 Tenaya Therapeutics, Inc. Hdac6 inhibitors for treatment of metabolic disease and hfpef

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2205732A1 (de) 1972-02-08 1973-08-16 Thomae Gmbh Dr K Neue 4-(4-biphenylyl)-butensaeurederivate
IT1044222B (it) * 1972-05-23 1980-03-20 Zambeletti Spa L Bifenilil alcanoilaminopiridine ad attivita anti infiammatoria di lunga durata
AT336594B (de) 1973-08-14 1977-05-10 Thomae Gmbh Dr K Verfahren zur herstellung neuer 3-(4- biphenylyl)-buttersaureamiden
US5196543A (en) 1989-10-17 1993-03-23 Delalande S.A. 3-aryloxazolidinone derivatives, process for their preparation and their use in therapy
EP0533753A1 (en) 1990-06-14 1993-03-31 Washington University Rna hydrolysis/cleavage
JP2969618B2 (ja) * 1995-06-27 1999-11-02 田辺製薬株式会社 ピリダジノン誘導体及びその製法
US5756507A (en) 1995-12-14 1998-05-26 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
JP3060454B2 (ja) * 1996-12-26 2000-07-10 田辺製薬株式会社 医薬組成物
US6114365A (en) 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
WO2001012189A1 (en) 1999-08-12 2001-02-22 Pharmacia Italia S.P.A. 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
ES2193839B1 (es) 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
CA2545422C (en) * 2003-12-03 2015-06-02 Cytopia Research Pty Ltd Tubulin inhibitors
CA2565599C (en) 2004-05-18 2012-07-31 Schering Corporation Substituted 2-quinolyl-oxazoles useful as pde4 inhibitors
JP2008518968A (ja) * 2004-10-29 2008-06-05 メルク エンド カムパニー インコーポレーテッド アンドロゲン受容体モジュレーターとしてのn−(ピリジン−3−イル)−2−フェニルブタンアミド
CN101137623B (zh) * 2005-03-15 2013-03-27 奈科明有限责任公司 N-磺酰基吡咯及其作为组蛋白脱乙酰酶抑制剂的用途
WO2007123953A2 (en) 2006-04-19 2007-11-01 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
EP2038272B8 (en) 2006-06-30 2013-10-23 Sunesis Pharmaceuticals, Inc. Pyridinonyl pdk1 inhibitors
JP2009185010A (ja) 2008-02-08 2009-08-20 Taisho Pharmaceutical Co Ltd グリシントランスポーター阻害剤を含有する医薬
FR2933700B1 (fr) * 2008-07-08 2010-07-30 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
MX2012001974A (es) 2009-08-19 2012-04-11 Ambit Biosciences Corp Compuestos de biarilo y metodos de uso de los mismos.
FR2952934B1 (fr) * 2009-11-23 2012-06-22 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
EP2545037A1 (en) * 2010-03-10 2013-01-16 Ingenium Pharmaceuticals GmbH Inhibitors of protein kinases
CA2793086C (en) 2010-03-18 2018-08-21 Institut Pasteur Korea Substituted imidazo[1,2-a]pyridine compounds and their use in the treatment of bacterial infections
EP3111937B1 (en) 2011-07-08 2020-06-17 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for treatment of liver cancer
US20130267712A1 (en) 2012-04-02 2013-10-10 Board Of Trustees Of Northern Illinois University Aromatic ketone synthesis with amide reagents and related reactions
CN105473559B (zh) 2013-03-15 2019-05-10 南洋理工大学 用于化学转化的羰基β-碳的活化
AR098475A1 (es) 2013-11-26 2016-06-01 Bayer Cropscience Ag Compuestos pesticidas y usos
WO2016067009A1 (en) 2014-10-28 2016-05-06 Redx Pharma Plc Compounds with activity against bacteria and mycobacteria
KR20170108150A (ko) * 2015-01-30 2017-09-26 더 유니버시티 오브 시드니 항암 화합물
SI3302448T1 (sl) 2015-06-04 2024-03-29 Aurigene Oncology Limited Substituirani heterociklični derivati kot inhibitorji cdk

Similar Documents

Publication Publication Date Title
JP2021508318A5 (enExample)
JP2019518766A5 (enExample)
JP2019524883A5 (enExample)
JP2019031560A5 (enExample)
JP2020510091A5 (enExample)
JP2017537940A5 (enExample)
JP2016513130A5 (enExample)
JP2017512833A5 (enExample)
JP2014501766A5 (enExample)
JP2017523169A5 (enExample)
JP2015537020A5 (enExample)
JP2018504437A5 (enExample)
JP2015508092A5 (enExample)
JP2017508816A5 (enExample)
JP2015531773A5 (enExample)
JP2017528502A5 (enExample)
JP2014521688A5 (enExample)
JP2017071634A5 (enExample)
JP2012513416A5 (enExample)
JP2016121196A5 (enExample)
JP2021512109A5 (enExample)
JP2012092103A5 (enExample)
JP2015521195A5 (enExample)
JP2017509586A5 (enExample)
JP2014506907A5 (enExample)